Could Torasemide be a prophylactic agent of contrast induced acute kidney injury? A review about this field

European Review for Medical and Pharmacological Sciences

Volumn 17, Issue 14, 2013, Pages 1845-1849

  Li, X M ^a   Jin, D X ^a   Cong, H L ^a  

^a Tianjin Chest Hospital   (China)

Author keywords

Acute kidney injury (AKI); Aldosterone antagonists; Contrast medium; Contrast induced nephropathy; Renin angiotensin aldosterone system; Torasemide

Indexed keywords

CONTRAST MEDIUM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; TORASEMIDE; DIURETIC AGENT; SULFONAMIDE;

ACUTE KIDNEY FAILURE; ARTICLE; CHEMOPROPHYLAXIS; CONTRAST INDUCED NEPHROPATHY; DRUG ACTIVITY; DRUG MECHANISM; HEALTH CARE COST; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; HYDRATION; KIDNEY PERFUSION; LENGTH OF STAY; MORBIDITY; MORTALITY; NEPHROTOXICITY; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; ACUTE LUNG INJURY; ANIMAL; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; PHYSIOLOGY;

ACUTE LUNG INJURY; ANIMALS; CONTRAST MEDIA; DIURETICS; HUMANS; RENIN-ANGIOTENSIN SYSTEM; SULFONAMIDES;

EID: 84884201603     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. QUINTAVALLE C, BRENCA M, DE MICCO F, FIORE D, ROMANO S, ROMANO MF, APONE F, BIANCO A, ZABATTA MA, TRONCONE G, BRIGUORI C, CONDORELLI G. In vivo and in vitro assessment of pathways involved in contrast media-induced renal cells apoptosis. Cell Death Dis 2011; 2: e155.
2. SHOUKAT S, GOWANI SA, JAFFERANI A, DHAKAM SH. Contrast-induced nephropathy in patients undergoing percutaneous coronary intervention. Cardiol Res Pract 2010; 2010. pii: 649164.
3. LI J, SOLOMON RJ. Creatinine increases after intravenous contrast administration: incidence and impact. Invest Radiol 2010; 45: 471-476.
4. HARJAI KJ, RAIZADA A, SHENOY C, SATTUR S, ORSHAW P, YAEGER K, BOURA J, ABOUFARES A, SPORN D, STAPLETON D. A comparison of contemporary definitions of contrast nephropathy in patients undergoing percutaneous coronary intervention and a proposal for a novel nephropathy grading system. Am J Cardiol 2008; 101: 812-819.
5. JABARA R, GADESAM RR, PENDYALA LK, KNOPF WD, CHRONOS N, CHEN JP, VIEL K, KING SB 3RD, MANOUKIAN SV. Impact of the definition utilized on the rate of contrast-induced nephropathy in percutaneous coronary intervention. Am J Cardiol 2009; 103: 1657-1662.
6. ABE M, KIMURA T, MORIMOTO T, KITA T. Incidence of and risk factors for contrast-induced nephropathy after cardiac catheterization in Japanese patients. Circ J 2009; 73: 1518-1522.
7. LAVILLE M, JUILLARD L. Contrast-induced acute kidney injury: how should at-risk patients be identified and managed? J Nephrol 2010; 23: 387-398.
8. CHEW DP, ASTLEY C, MOLLOY D, VAILE J, DE PASQUALE CG, AYLWARD P. Morbidity, mortality and economic burden of renal impairment in cardiac intensive care. Intern Med J 2006; 36: 185-192.
9. LEVY EM, VISCOLI CM, HORWITZ RI. The effect of acute renal failure on mortality. A cohort analysis. JAMA 1996; 275: 1489-1494.
10. RIHAL CS, TEXTOR SC, GRILL DE, BERGER PB, TING HH, BEST PJ, SINGH M, BELL MR, BARSNESS GW, MATHEW V, GARRATT KN, HOLMES DR JR. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002; 105: 2259-2264.
11. ROGHI A, SAVONITTO S, CAVALLINI C,ARRAIZ G, ANGOLI L, CASTRIOTA F, BERNARDI G, SANSA M, DE SERVI S, PITSCHEIDER W, DANZI GB, REIMERS B, KLUGMANN S, ZANINOTTO M, ARDISSINO D; ATHEROSCLEROSIS, THROMBOSIS AND VASCULAR BIOLOGY STUDY GROUP AND THE ITALIAN SOCIETY FOR INVASIVE CARDIOLOGY INVESTIGATORs. Impact of acute renal failure following percutaneous coronary intervention on long-term mortality. J Cardiovasc Med (Hagerstown 2008; 9: 375-381.
12. RAY S, DUTTA A. Contrast-induced nephropathy. Indian Heart J 2008; 60: 133-138.
13. DEVRIM E, CETIN M, NAMUSLU M, ERGÜDER IB, CETIN R, DURAK I. Oxidant stress due to non ionic low osmolar contrast medium in rat kidney. Indian J Med Res 2009; 130: 433-436.
14. BRIGUORI C, QUINTAVALLE C, DE MICCO F, CONDORELLI G. Nephrotoxicity of contrast media and protective effects of acetylcysteine. Arch Toxicol 2011; 85: 165-173.
15. GUPTA RK, KAPOOR A, TEWARI S, SINHA N, SHARMA RK. Captopril for prevention of contrast-induced nephropathy in diabetic patients: a randomised study. Indian Heart J 1999; 51: 521-526.
16. PERSSON PB, HANSELL P, LISS P. Pathophysiology of contrast medium-induced nephropathy. Kidney Int 2005; 68:14-22.
17. DETRENIS S, MESCHI M, MUSINI S, SAVAZZI G. Lights and shadows on the pathogenesis of contrast-induced nephropathy: state of the art. Nephrol Dial Transplant 2005; 20: 1542-1550.
18. LARSON TS, HUDSON K, MERTZ JI, ROMERO JC, KNOX FG. Renal vasoconstrictive response to contrast medium. The role of sodium balance and the renin-angiotensin system. J Lab Clin Med 1983; 101: 385-391.
19. SENDESKI M, PATZAK A, PALLONE TL, CAO C, PERSSON AE, PERSSON PB. Iodixanol, constriction of medullary descending vasa recta, and risk for contrast medium-induced nephropathy. Radiology 2009; 251: 697-704.
20. SENDESKI M, PATZAK A, PERSSON PB. Constriction of the vasa recta, the vessels supplying the area at risk for acute kidney injury, by four different iodinated contrast media, evaluating ionic, nonionic, monomeric and dimeric agents. Invest Radiol 2010; 45: 453-457.
21. WEN X, MURUGAN R, PENG Z, KELLUM JA. Pathophysiology of acute kidney injury: a new perspective. Contrib Nephrol 2010; 165: 39-45.
22. Lai KN, Leung JC, Tang SC. The renin-angiotensin system. Contrib Nephrol 2011; 170: 135-144.
23. DU CHEYRON D, FRADIN S, RAMAKERS M, TERZI N, GUILLOTIN D, BOUCHET B, DAUBIN C, CHARBONNEAU P. Angiotensin converting enzyme insertion/deletion genetic polymorphism: its impact on renal function in critically ill patients. Crit Care Med 2008; 36: 3178-3183.
24. RAFIQ K, HITOMI H, NAKANO D, NISHIYAMA A. Pathophysiological roles of aldosterone and mineralocorticoid receptor in the kidney. J Pharmacol Sci 2011; 115: 1-7.
25. BRIET M, SCHIFFRIN EL. Aldosterone: effects on the kidney and cardiovascular system. Nat Rev Nephrol 2010; 6: 261-273.
26. NISHIYAMA A, YAO L, NAGAI Y,MIYATA K, YOSHIZUMI M, KAGAMI S, KONDO S, KIYOMOTO H, SHOKOJI T, KIMURA S, KOHNO M, ABE Y. Possible contributions of reactive oxygen species and mitogen-activated protein kinase to renal injury in aldosterone/salt-induced hypertensive rats. Hypertension 2004; 43: 841-848.
27. MA J, WEISBERG A, GRIFFIN JP, VAUGHAN DE, FOGO AB, BROWN NJ. Plasminogen activator inhibitor-1 deficiency protects against aldosterone-induced glomerular injury. Kidney Int 2006; 69: 1064- 1072.
28. LI X, LI T, CONG H. Is angiotensin-converting enzyme inhibitor a contraindication for contrast-induced nephropathy prophylaxis? A Review About its Paradox. Cardiovasc Ther 2011. [Epub ahead of print]
29. LI X, LI T, FU N, HU Y, CONG H. Is angiotensin-converting enzyme inhibitor appropriate for contrastinduced nephropathy? A metaanalysis about this field. Int J Cardiol 2012; 155: 486-488.
30. FLEMING I, KOHLSTEDT K, BUSSE R. New fACEs to the renin-angiotensin system. Physiology (Bethesda) 2005; 20: 91-95.
31. RUILOPE LM. Renin-angiotensin-aldosterone system blockade and renal protection: angiotensinconverting enzyme inhibitors or angiotensin II receptor blockers? Acta Diabetol 2005; 42: 33-41.
32. TOPRAK O, CIRIT M, BAYATA S,YEIL M. Review of the radiocontrast nephropathy risk profi les and risk stratifi cation. Anadolu Kardiyol Derg 2004; 4: 331-335.
33. CALDICOTT WJ, HOLLENBERG NK, ABRAMS HL. Characteristics of response of renal vascular bed to contrast media. Evidence for vasoconstriction induced by renin-angiotensin system. Invest Radiol 1970; 5: 539-547.
34. BREWS TER UC, PERAZEL LA MA. The renin-angiotensin- aldosterone system and the kidney: effects on kidney disease. Am J Med 2004; 116: 263-272.
35. MIANA M, DE LAS HERAS N, RODRIGUEZ C, SANZ-ROSA D, MARTIN-FERNANDEZ B, MEZZANO S, LAHERA V, MARTINEZ- GONZALEZ J, CACHOFEIRO V. Effect of eplerenone on hypertension-associated renal damage in rats: potential role of peroxisome proliferator activated receptor gamma (PPAR-). J Physiol Pharmacol 2011; 62: 87-94.
36. BAGSHAW SM, DELANEY A, HAASE M, GHALI WA, BELLOMO R. Loop diuretics in the management of acute renal failure: a systematic review and metaanalysis. Crit Care Resusc 2007; 9: 60-68.
37. KIDO H, OHTAKI Y. Torasemide (LUPRAC: a review of its pharmacological and clinical profile. Nippon Yakurigaku Zasshi 2001; 118: 97-105.
38. HARADA K, IZAWA H, NISHIZAWA T, HIRASHIKI A, MURASE Y, KOBAYASHI M, ISOBE S, CHENG XW, NODA A, NAGATA K, YOKOTA M, MUROHARA T. Beneficial effects of torasemide on systolic wall stress and sympathetic nervous activity in asymptomatic or mildly symptomatic patients with heart failure: comparison with azosemide. J Cardiovasc Pharmacol 2009; 53: 468-473.
39. UCHIDA T, YAMANAGA K, NISHIKAWA M,OHTAKI Y, KIDO H, WATANABE M. Anti-aldosteronergic effect of torasemide. Eur J Pharmacol 1991; 205:145-150.
40. UCHIDA T, YAMANAGA K, KIDO H, OHTAKI Y, WATANABE M. Diuretic and vasodilating actions of torasemide. Cardiology 1994; 84: 14-17.
41. LIGUORI A, CASINI A, DI LORETO M, ANDREINI I, NAPOLI C. Loop diuretics enhance the secretion of prostacyclin in vitro, in healthy persons, and in patients with chronic heart failure. Eur J Clin Pharmacol 1999; 55: 117-124.
42. MCCULLOUGH PA, TUMLIN JA. Prostaglandin-based renal protection againstcontrast-induced acute kidney injury. Circulation 2009; 120: 1749-1751.
43. HUBER W, SCHIPEK C, ILGMANN K, PAGE M, HENNIG M, WACKER A, SCHWEIGART U, LUTILSKY L, VALINA C, SEYFARTH M, SCHÖMIG A, CLASSEN M. Effectiveness of theophylline prophylaxis of renal impairment after coronary angiography in patients with chronic renal insufficiency. Am J Cardiol 2003; 91: 1157- 1162.
44. BREZIS M, GREENFELD Z, SHINA A, ROSEN S. Angiotensin II augments medullary hypoxia and predisposes to acute renal failure. Eur J Clin Invest 1990; 20: 199-207.